The AD-VISE Study set out to characterize the real-world utilization patterns, effectiveness, and durability of response to upadacitinib (Rinvoq, AbbVie) 15mg and 30mg among adults and adolescents with atopic dermatitis (AD) who were taking it for at least 12 months. Study Author Melinda Gooderham, MSc, MD, FRCPC, a Dermatologist and Medical Director of the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, reviews the topline data and discusses the role of shared decision-making when choosing an appropriate AD therapy. The data was presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France.
Key Takeaways:
- Most AD patients who received upadacitinib achieved improvements in skin clearance and itch relief at two months, and rates were generally maintained through 12 months.
- Between 31.1% (Month 2) and 28.7% (Month 12) of patients achieved minimal disease activity.
- AD patients reported improvement in quality of life beginning at two months, with generally similar results at 12 months.
- The AD-VISE Study is ongoing.
